Lyth Johan, Gialias Pantelis, Husberg Magnus, Bernfort Lars, Bjerner Tomas, Wiberg Maria Kristoffersen, Levin Lars-Åke, Gustafsson Håkan
Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Department of Radiology in Linköping, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Eur Radiol. 2025 Jul 19. doi: 10.1007/s00330-025-11821-9.
To evaluate the cost-effectiveness of AI-assisted digital mammography (AI-DM) compared to conventional biennial breast cancer digital mammography screening (cDM) with double reading of screening mammograms, and to investigate the change in cost-effectiveness based on four different sub-strategies of AI-DM.
A decision-analytic state-transition Markov model was used to analyse the decision of whether to use cDM or AI-DM in breast cancer screening. In this Markov model, one-year cycles were used, and the analysis was performed from a healthcare perspective with a lifetime horizon. In the model, we analysed 1000 hypothetical individuals attending mammography screenings assessed with AI-DM compared with 1000 hypothetical individuals assessed with cDM.
The total costs, including both screening-related costs and breast cancer-related costs, were €3,468,967 and €3,528,288 for AI-DM and cDM, respectively. AI-DM resulted in a cost saving of €59,320 compared to cDM. Per 1000 individuals, AI-DM gained 10.8 quality-adjusted life years (QALYs) compared to cDM. Gained QALYs at a lower cost means that the AI-DM screening strategy was dominant compared to cDM. Break-even occurred at the second screening at age 42 years.
This analysis showed that AI-assisted mammography for biennial breast cancer screening in a Swedish population of women aged 40-74 years is a cost-saving strategy compared to a conventional strategy using double human screen reading. Further clinical studies are needed, as scenario analyses showed that other strategies, more dependent on AI, are also cost-saving.
Question To evaluate the cost-effectiveness of AI-DM in comparison to conventional biennial breast cDM screening. Findings AI-DM is cost-effective, and the break-even point occurred at the second screening at age 42 years. Clinical relevance The implementation of AI is clearly cost-effective as it reduces the total cost for the healthcare system and simultaneously results in a gain in QALYs.
评估人工智能辅助数字化乳腺摄影(AI-DM)与传统的每两年进行一次且对筛查乳腺摄影进行双人阅片的乳腺癌数字化乳腺摄影筛查(cDM)相比的成本效益,并基于AI-DM的四种不同子策略研究成本效益的变化。
采用决策分析状态转移马尔可夫模型分析在乳腺癌筛查中使用cDM还是AI-DM的决策。在这个马尔可夫模型中,使用一年周期,从医疗保健角度进行终身分析。在模型中,我们分析了1000名接受AI-DM评估的乳腺摄影筛查的假设个体,并与1000名接受cDM评估的假设个体进行比较。
AI-DM和cDM的总成本(包括筛查相关成本和乳腺癌相关成本)分别为3468967欧元和3528288欧元。与cDM相比,AI-DM节省了59320欧元的成本。每1000名个体中,与cDM相比,AI-DM获得了10.8个质量调整生命年(QALY)。以更低成本获得QALY意味着与cDM相比,AI-DM筛查策略占主导地位。盈亏平衡点出现在42岁的第二次筛查时。
该分析表明,在瑞典40-74岁女性人群中,每两年进行一次乳腺癌筛查的人工智能辅助乳腺摄影与使用双人人工阅片的传统策略相比是一种节省成本的策略。由于情景分析表明,其他更依赖人工智能的策略也具有成本效益,因此需要进一步的临床研究。
问题 评估AI-DM与传统的每两年进行一次的cDM筛查相比的成本效益。发现 AI-DM具有成本效益,盈亏平衡点出现在42岁的第二次筛查时。临床相关性 人工智能的实施显然具有成本效益,因为它降低了医疗系统的总成本,同时带来了QALY的增加。